GE s New Growth Strategy May Complement CodeLink s Lengthy Developmental Horizon | GenomeWeb

If General Electric’s bid to acquire Amersham is approved, the giant conglomerate will inherit an as-yet-unprofitable microarray platform in an emerging market that occupies a modest, if growing, revenue base.

Considering that GE has set its sites on buying the British life science-technology company with the aim of reviving battered net earnings, it may be tough to see where Amersham’s personalized medicine play, in the form of its nascent CodeLink product line, can help drive short-term revenue.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.